Optimization of 3-(1H-Indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists

Journal of Medicinal Chemistry

Volumn 40, Issue 17, 1997, Pages 2706-2725

  Henke, Brad R ^a   Aquino, Christopher J ^a   Birkemo, Larry S ^a   Croom, Dallas K ^a,b   Dougherty Jr , Robert W ^a,b   Ervin, Gregory N ^a,c   Grizzle, Mary K ^a   Hirst, Gavin C ^a,d   James, Michael K ^a,b   Johnson, Michael F ^a   Queen, Kennedy L ^a   Sherrill, Ronald G ^a   Sugg, Elizabeth E ^a   Suh, Edward M ^a   Szewczyk, Jerzy W ^a   Unwalla, Rayomand J ^a,e   Yingling, Jeff ^a   Willson, Timothy M ^a  

^a GLAXOSMITHKLINE   (United States)

^b Inspire Pharmaceuticals   (United States)

^c BRIGHAM YOUNG UNIVERSITY   (United States)

^d BASF Bioresearch Corporation   (United States)

^e WYETH AYERST RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [3 (1H INDAZOL 3 YLMETHYL) 2,4 DIOXO 5 PHENYL 2,3,4,5 TETRAHYDROBENZO[B][1,4]DIAZEPIN 1 YL] N ISOPROPYL N (4 METHOXYPHENYL)ACETAMIDE; ASPERLICIN; BENZODIAZEPINE DERIVATIVE; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; GW 5823; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DOSE RESPONSE; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; GALLBLADDER EMPTYING; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ALKYLATION; ANIMALS; BENZODIAZEPINES; BENZODIAZEPINONES; CHO CELLS; CRICETINAE; DEVAZEPIDE; GALLBLADDER; GUINEA PIGS; HORMONE ANTAGONISTS; INDAZOLES; MICE; MODELS, CHEMICAL; RATS; RECEPTOR, CHOLECYSTOKININ A; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, CHOLECYSTOKININ;

EID: 15644365451     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970265x     Document Type: Article

References (61)

1. (a) Crawley, J. N.; Corwin, R. L. Biological Actions of Cholecystokinin. Peptides 1994, 4, 731-755.
2. (b) Larson, L.-I.; Rehfeld, J. F. Localisation and Molecular Heterogeneity of Cholocystokinin in the Central and Peripheral Nervous System. Brain Res. 1979, 165, 201-218.
3. (c) Reeve, J. R., Jr.; Eysselein, V.; Walsh, J. H.; Ben Avram, C. M.; Shively, J. E. New Molecular Forms of Cholecystokinin. Microsequence Analysis of Forms Previously Characterized by Chromatographic Methods. J. Biol. Chem. 1986, 261, 16392-16397.
4. Schwartz, G. J.; McHugh, P. R.; Moran, T. H. Gastric Loads and Cholecystokinin Synergistically Stimulate Rat Vagal Afferents. Am. J. Physiol. 1993, 265, R872-R876.
5. Dourish, C. T.; Ruckert, A. C.; Tattersall, F. D.; Iversen, S. D. Evidence that Decreased Feeding Induced by Systemic Injection of Cholecystokinin is Mediated by CCK-A Receptors. Eur. J. Pharmacol. 1989, 173, 233-234.
6. Dourish, C. T.; Hill, D. R. Classification and Function of CCK Receptors. Trends Pharmacol. Sci. 1987, 8, 207-208.
7. Kissileff, H. R.; Pi-Sunyer, F. X.; Thornton, J.; Smith, G. P. C-Terminal Octapeptide of Cholecystokinin Decreases Food Intake in Man. Am. J. Clin. Nutr. 1981, 34, 154-160.
8. Pi-Sunyer, F. X.; Kissileff, H. R.; Thornton, J.; Smith, G. P. C-Terminal Octapeptide of Cholecystokinin Decreases Food Intake in Obese Men. Physiol. Behav. 1982, 29, 627-630.
9. (a) Sitzmann, J. V.; Pitt, H. A.; Steinborn, P. A.; Pasha, Z. R.; Sanders, R. C. Cholecystokinin Prevents Parenteral Nutrition Induced Biliary Sludge in Humans Surg. Gynacol. Obstetrics 1990, 170, 25-31.
10. (b) Froehlich, F.; Gonvers, J. J.; Fried, M. Role of Nutrient Fat and Cholecystokinin in Regulation of Gallbladder Emptying in Man. Dig. Dis. Sci. 1995, 40, 529-533.
11. (c) Roslyn, J. J.; DenBesten, L.; Pitt, H. A.; Kuchenbecker, S.; Polarek, J. W. Effects of Cholecystokinin on Gallbladder Stasis and Cholesterol Gallstone Formation. J. Surg. Res. 1981, 30, 200-204.
12. Silverstone, T. In Obesity: Theory and Therapy; Stunkard, A. J., Wadden, T. A., Eds.; Raven Press, Ltd.: New York, 1993; pp 275-283.
13. Henke, B. R.; Willson, T. M.; Sugg, E. E.; Croom, D. K.; Dougherty, R. W., Jr.; Queen, K. L.; Birkemo, L. S.; Ervin, G. N.; Grizzle, M. K.; Johnson, M. F.; James, M. K. 3-(1H-Indazol-3-ylmethyl)-1,5-benzodiazepines: CCK-A Agonists That Demonstrate Oral Activity as Satiety Agents. J. Med. Chem. 1996, 39, 2655-2658.
14. Abdel-Magid, A. F.; Maryanoff, C. A.; Carson, K. G. Reductive Amination of Aldehydes and Ketones by Using Sodium Triacetoxyborohydride. Tetrahedron Lett. 1990, 31, 5595-5598.
15. Indole-3-carboxylic acid is commercially available from the Aldrich Chemical Co. Leading references to the preparation of other derivatives include the following: (a) Indazole-3-carboxylic acid: Ferrari, M; Ripa, A; Ripa, G; Sisti, M. An improved synthesis of indazole-3-carboxylic acid. J. Heterocycl. Chem. 1989, 26, 531-532.
16. (b) Benzothiophene-3-carboxylic acid: Bonjouklian, R. A direct synthesis of benzothiophene-3-carboxylic acid from benzothiophene. Synth. Commun. 1985, 15, 711-713.
17. (c) 4,5,6,7-Tetrahydro-1H-indazole-3-carboxylic acid: Ainsworth, C. Indazole Analog of Tryptamine: A New Synthesis of Indazoles. J. Am. Chem. Soc. 1957, 79, 5242-5245.
18. (d) Benzisoxazole- and benzisothiazole-3-carboxylic acid: Hrib, N. J.; Jurcak, J. G.; Burgher, K. L.; Conway, P. G.; Hartman, H. B.; Kerman, L. L.; Roehr, J. E.; Woods, A. T. Benzisoxazole- and Benzisothiazole-3-carboxamides as Potential Atypical Antipsychotic Agents. J. Med. Chem., 1994, 37, 2308-2314.
19. Horner, L.; Oediger, H.; Hoffman, H. Ann. 1959, 626, 26-34.
20. Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis, 2nd ed.; John Wiley and Sons, Inc.: New York, 1991.
21. Snyder, H. R.; Thompson, C. B.; Hinman, R. L. The Synthesis of an Indazole Analog of DL-Tryptophan. J. Am. Chem. Soc. 1952, 74, 2009-2012.
22. March, J. Advanced Organic Chemistry, 3rd ed.; John Wiley & Sons: New York, 1985; pp 608-626.
23. (a) 3-Methylhenzisoxazole: Stokker, G. Preparation of 1,2-benzisoxazoles from Salicylaldoximes via trichloroacetyl isocyanate. J. Org. Chem. 1983, 48, 2613-15.
24. (b) 3-Methyl-1H-pyrazolo[3,4-b]pyridine: Abignente, E.; De Caprariis, P.; Stein, M. L. New Isoxazolo[5,4-b]pyridine-3-acetic Acids. Farmaco, Ed. Sci. 1975, 30, 992-1000.
25. Heck, R. F. Palladium Reagents in Organic Synthesis. In Best Synthetic Methods, 2nd ed.; Katritzky, A. R., Meth-Cohn, O., Rees, C. W., Eds.; Academic Press: London, 1985; pp 276-287.
26. Etchevarren, A. M.; Stille, J. K. Palladium-Catalyzed Coupling of Aryl Triflates with Organostannanes J. Am. Chem. Soc. 1987, 109, 5478-5486.
27. Gadwood, R. C.; Rubino, M. R.; Nagarajan, S. C.; Michel, S. T. Generation of (1-Alkoxycyclopropyl)lithium Reagents. J. Org. Chem. 1985, 50, 3255-3260.
28. Kwan, H. B.; McKee, B. H.; Stille, J. K. Palladium-Catalyzed Coupling Reactions of (α-Ethoxyvinyl)trimethylstannane with Vinyl and Aryl Triflates. J. Org. Chem. 1990, 55, 3114-3118.
29. Aquino, C. J.; Armour, D. R.; Berman, J. M.; Birkemo, L. S.; Carr, R. A. E.; Croom, D. K.; Dezube, M.; Dougherty, R. W.; Ervin, G. N.; Grizzle, M. K.; Head, J. E.; Hirst, G. C.; James, M. K.; Johnson, M. F.; Long, J. E.; Miller, L. J.; Queen, K. L.; Rimele, T. J.; Smith, D. N.; Sugg, E. E. Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity I. Optimization of the Agonist "Trigger". J. Med. Chem. 1996, 39, 562-569.
30. Evans, B. E.; Bock, M. G.; Rittle, K. E; Dipardo, R. M.; Whitter, W. L; Veber, D. L.; Anderson, P. S.; Freidinger, R. M. Design of Potent, Orally Effective, Nonpeptidyl Antagonists of the Peptide Hormone Cholecystokinin. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 4918-4922.
31. 2 (A-71623). J. Med. Chem. 1995, 38, 207-211.
32. (a) Ulrich, C. D.; Ferber, I.; Holicky, E.; Hadac, E.; Buell, G.; Miller, L. J. Molecular Cloning and Functional Expression of the Human Gallbladder Cholecystokinin A Receptor. Biochem. Biophys. Res. Commun. 1993, 193, 204-211.
33. (b) de Weerth, A.; Pisegna, J. R.; Huppi, K.; Wank, S. A. Molecular Cloning, Functional Expression and Chromosomal Localization of the Human Cholecystokinin Type A Receptor. Biochem. Biophys. Res. Commun. 1993, 194, 811-818.
34. (a) Pisegna, J. R.; de Weerth, A.; Huppi, K.; Wank, S. A. Molecular Cloning of the Human Brain and Gastric Cholecystokinin Receptor: Structure, Functional Expression and Chromosomal Localization. Biochem. Biophys. Res. Commun. 1992, 189, 296-303.
35. (b) Lee, Y. M.; Beinborn, M.; McBride, E. W.; Lu, M.; Kolakowski, L. F., Jr.; Kopin, A. S. The Human Brain Cholecystokinin-B/Gastrin Receptor. Cloning and Characterization. J. Biol. Chem. 1993, 268, 8164-8169.
36. Makovec, F.; Bani, M.; Cereda, R.; Chiste, R.; Pacini, M. A.; Revel, L.; Rovati, L. C. Antispasmodic Activity on the Gallbladder of the Mouse of CR1409 (Lorglumide), a Potent Antagonist of Peripheral Chlolecystokinin. Pharmacol. Res. Commun. 1987, 19, 41-51.
37. For the effects of CCK on rat feeding behavior by peripheral and centrally mediated pathways and gastric emptying, see: (a) Della-Fera, M. A.; Coleman, B. D.; Baile, C. A. CNS injection of CCK in rats: Effects on Real and Sham Feeding and Gastric Emptying. Am. J. Physiol. 1990, 258, R1165-R1169.
38. (b) Crawley, J. Clarification of the Behavioral Functions of Peripheral and Central Cholecystokinin: Two Separate Peptide Pools. Peptides 1985, 6, 129-36.
39. (c) Moran, T. H.; McHugh, P. R. Cholecystokinin Suppresses Food Intake by Inhibiting Gastric Emptying. Am. J. Physiol. 1982, 242, R491-R497.
40. Willson, T. M.; Henke, B. R.; Momtahen, T. M.; Myers, P. L.; Sugg, E. E., Unwalla, R. J.; Croom, D. K.; Grizzle, M. K.; Johnson, M. F.; Queen, K. L.; Rimele, T. R.; Yingling, J. D.; James, M. K. 3-[2-(N-Phenylacetamide)]-1,5-benzodiazepines: Orally Active, Binding Selective CCK-A Agonists. J. Med. Chem. 1996, 39, 3030-3034.
41. Hirst, G. C.; Aquino, C.; Birkemo, L.; Croom, D. K.; Dezube, M.; Dougherty, R.W.; Ervin, G. N.; Grizzle, M. K.; Henke, B.; James, M. K.; Johnson, M. F.; Momtahen, T.; Queen, K. L.; Sherrill, R. G.; Szewczyk, J.; Willson, T. M.; Sugg, E. E. Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity (II): Optimization of the C3 Amino Substituent. J. Med. Chem. 1996, 39, 5236-5245.
42. Chang, R. S.; Lotti, V. J.; Monaghan, R. L.; Birnbaum, J.; Stapley, E. O.; Goetz, M. A.; Albers-Schonberg, G.; Patchett, A. A.; Liesch, J. M.; Hensens, O. D. A Potent Nonpeptide Cholecystokinin Antagonist Selective for Peripheral Tissues Isolated from Aspergillus Alliaceus. Science 1985, 230, 177-179.
43. (a) Evans, B. E.; Bock, M. G. Promiscuity in Receptor Ligand Research: Benzodiazepine-based Cholecystokinin Antagonists. Adv. Med. Chem. 1993, 2, 111-52.
44. (b) Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Gould, N. P.; Lundell, G. F.; Homnick, C. F.; Veber, D.F.; Anderson, P.S.; Chang, R.S. L.; Lotti, V. J.; Cerino, D. J.; Chen, T. B.; King, P. J.; Kunkel, K. A.; Springer, J. P.; Hirshfield, J. Design of Nonpeptidal Ligands for a Peptide Receptor: Choleeystokinin Antagonists. J. Med. Chem. 1987, 30, 1229-1239.
45. (c) Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S.; Chang, R. S. L.; Lotti, V. J.; Cerino, D. J.; Chen, T. B.; King, P. J.; Kunkel, K.A.; Springer, J. P.; Hirshfield, J. Methods for Drug Discovery: Development of Potent, Selective, Orally Effective Cholecystokinin Antagonists. J. Med. Chem. 1988, 31, 2235-2246.
46. (d) Bock, M. G.; Dipardo, R. M.; Evans, B. E.; Rittle, K. E.; Whitter, W. L.; Veber, D. F.; Anderson, P. S.; Freidinger, R. M. Benzodiazepine Gastrin and Brain CCK Receptor Ligands: L365, 260. J. Med. Chem. 1989, 32, 13-16.
47. (d) Yu, M. J.; Thrasher, K. J.; McCowan, J. R.; Mason, N. R.; Mendelsohn, L. G. Quinazoline Cholecystokinin-B Receptor Ligands. J. Med. Chem. 1991, 34, 1505-1508.
48. (e) Yu, M. J.; McCowan, J. R.; Mason, N. R.; Deeter, J. B.; Mendelsohn, L. G. Synthesis and X-ray Crystallographic Analysis of Quinazoline Cholecystokinin/Gastrin Receptor Ligands. J. Med. Chem. 1992, 35, 2534-2542.
49. (a) Hermkens, P. H. H.; Ottenheijm, H. C. J.; van der Werf-Pieters, J. M. L.; Broekkamp, C. L. E.; de Boer, T.; van Nispen, J. W. CCK-A Agonists: Endeavours Involving Structure-Activity Relationship Studies. Red. Trav. Chim. Pays-Bas 1993, 112, 95-106.
50. (b) Shiosaki, K.; Lin, C. W.; Kopecka, H.; Craig, R.; Wagenaar, F. L.; Bianchi, B.; Miller, T.; Witte, D.; Nadzan, A. M. Development of CCK-Tetrapeptide Analogues as Potent and Selective CCK-A Receptor Agonists. J. Med. Chem. 1990, 33, 2950-2952.
51. (c) Shiosaki, K.; Lin, C. W.; Kopecka, H.; Tufano, M. D.; Bianchi, B. R.; Miller, T. R.; Witte, D. G.; Nadzan, A. M. Boc-CCK-4 Derivatives Containing Side-Chain Ureas as Potent and Selective CCK-A Receptor Agonists. J. Med. Chem. 1991, 34, 2837-2842.
52. (d) Dezube, M.; Sugg, E. E.; Birkemo, L. S.; Croom, D. K.; Dougherty, R. W., Jr.; Ervin, G. N.; Grizzle, M. K.; James, M. K.; Johnson, M. F.; Mosher, J.T.; Queen, K. L.; Rimele, T. J.; Sauls, H. R.; Triantafillou, J. A Modification of Receptor Selectivity and Functional Activity in Cholecystokinin Peptoid Ligands. J. Med. Chem. 1995, 38, 3384-3390.
53. SPARTAN, Version 3.5, Wavefunction, Inc. 18401 Von Karman Ave., #370, Irvine, CA 92715. The ab initio molecular orbital calculations were carried out using the SPARTAN program on a Silicon Graphics Indigo workstation on the C3 heterocyclic fragment only. The 3-21G* basis set was used, and full geometry optimizations were performed. Electrostatic potential surface color-coded onto the electron density was calculated in each case.
54. (a) Grider, J. Role of Cholecystokinin in the regulation of gastrointestinal motility J. Nutr. 1994, 124, 1334S-1339S.
55. (b) Reidelberger, R. D.; Varga, G.; Liehr, R.-M.; Castellanos, D. A.; Rosenquist, G. L.; Wong, H. C.; Walsh, J. H. Cholecystokinin suppresses food intake by a nonendocrine mechanism in rats. Am. J. Physiol. 1994, 267, R901-R908.
56. Scarpignato, C.; Capovilla, T.; Bertaccini, G. Action of caerulein on gastric emptying of the conscious rat. Arch. Int. Pharmacodyn. Ther. 1980, 246, 286-294.
57. Liddle, R. A.; Gertz, B. J.; Kanayama, S.; Beccaria, L.; Coker, L. D.; Turnbull, T. A.; Morita, E. T. 1989, Effects of a novel cholecystokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in humans. Implications for the physiology of CCK. J. Clin. Invest. 1989, 84, 1220-1225.
58. Sugg, E. E.; Birkemo, L.; Gan, L.-S.; Tippin, T. K. Orally active nonpeptide CCK-A agonists. In Integration of Pharmaceutical Discovery and Development: Case Histories; Borchardt, R. T., Freidinger, R. M., Sawyer, T., Smith, P., Eds.; Plenum Publishing Corp.: New York, in press.
59. Bock, M. G.; DiPardo, R. M.; Evans, B. E.; Rittle, K. E.; Whitter, W. L.; Garsky, V. M.; Gilbert, K. F.; Leighton, J. L.; Carson, K. L.; Melin, E. C.; Veber, D. F.; Chang, R. S. L.; Lotti, V. J.; Freedman, S. B.; Smith, A. J.; Patel, S.; Anderson, P. S.; Freidinger, R. M. Development of 1,4-Benzodiazepine Cholecystokinin Type B Antagonists. J. Med. Chem. 1993, 36, 4276-4292.
60. Still, W. C.; Kahn, M.; Mitra, A. J. Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution. J. Org. Chem. 1978, 43, 2923-2925.
61. 3 Receptor. J. Med. Chem. 1987, 30, 1535-1537.